This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Expanding the potential patient population for pulsed field ablation, results from the SINGLE SHOT CHAMPION study suggest PFA might be just as good as cryoballoon ablation for patients with paroxysmal AFib. PFA has shown advantages in procedure time and safety, but its effectiveness is unproven compared to cryoballoon ablation.
(MedPage Today) -- The efficacy of catheter ablation for heart failure (HF) patients with atrial fibrillation (Afib or AF) hinged on the phenotype of disease, researchers reported based on a meta-analysis. Compared with conventional rate or rhythm.
16, 2025 Primary results from the DEFINE AFib clinical study show the Medtronic LINQ family of insertable cardiac monitors (ICM), paired with a novel algorithm, were able to detect atrial fibrillation episodes and properly risk stratify patients as high risk prior to an AF-related healthcare utilization 80% of the time. Piccini, M.D.,
Research Highlights: Treating gum disease within three months after a heart procedure to correct an irregular heart rhythm, known as atrial fibrillation (AFib), may lower the chances of it reoccurring. Inflamed gums may predict AFib recurrence after.
Treating gum disease in the three months after a procedure to correct an irregular heartbeat known as atrial fibrillation (AFib) may lower oral inflammation and may reduce AFib recurrence, according to new research published today in the Journal of the American Heart Association.
Titled "Real-world Data Affirms Safety and Effectiveness of Low/Zero Fluoroscopy Atrial Fibrillation Ablation," the study was presented as a late-breaker at the 29th Annual International AF Symposium. Biosense Webster's zero fluoroscopy workflow is the first and only such workflow available in a radiofrequency (RF) cardiac ablation device.
September is National Atrial Fibrillation (AFib) Awareness Month, a time dedicated to raising awareness about one of the most common yet often misunderstood heart conditions. Physicians have a crucial role in recognizing, diagnosing, and managing AFib to prevent its potentially life-threatening complications.
September is National Atrial Fibrillation (AFib) Awareness Month, a time dedicated to raising awareness about one of the most common yet often misunderstood heart conditions. Physicians have a crucial role in recognizing, diagnosing, and managing AFib to prevent its potentially life-threatening complications.
11, 2025, at HonorHealth Research Institute, Rahul Doshi, M.D., Using the same catheter, he also was able to easily switch to radiofrequency ablation, which has traditionally been used to treat Afib by scarring the damaged part of the heart using heat. Learn more at HonorHealth.com/research. 12, 2025 On Feb.
During its Annual Conference, HRS 2024, the Heart Rhythm Society (HRS) announced findings from three new studies demonstrating the safety and efficacy of pulsed field ablation (PFA), a nonthermal ablation treatment for patients with atrial fibrillation (AF). See full findings from the FARADISE, admIRE Study, and Advent Trial here.
The VARIPULSE Platform is comprised of the VARIPULSE Catheter, a fully integrated variable-loop multielectrode catheter; the TRUPULSE Generator, a pulsed field ablation (PFA) generator; and the CARTO 3 System VARIPULSE Software, which provides full integration with the world's leading 3D cardiac mapping system.
Signify Research has just released a deep-dive qualitative analysis of developments around the use of AI to analyze and interpret electrocardiograms (ECGs), one of the world’s most ubiquitous diagnostic tests for cardiac disease. Fertile Partnerships Ongoing research partnerships have driven much of recent developments seen in the market.
The whole process can easily take 10-15 years and therefore patients may continue to be managed in sub-optimal manner for this duration of time even when there is available research to say that things could be done better. Today I wanted to talk about some troubling research in the field of AF. What about ablation?
Boston Scientific made what could become a major addition to its electrophysiology portfolio, acquiring AFib mapping startup Cortex, Inc. Cortex gives Boston Scientific a new mapping technology that detects AFib signs and triggers outside of the pulmonary veins, and can help EP teams develop ablation strategies for more complex AFib cases.
OPTION Trial : LAAC after AFibablation was associated with lower risks of major bleeding compared to oral anticoagulation. VANISH2 Trial : Catheter ablation as first-line therapy reduced VT episodes more effectively than antiarrhythmic drugs in ischemic cardiomyopathy patients. Access the full study. View the study.
What happened to top 10 cardiology research papers of 2023 ? In that sense, every year, we see more than 100s of RCT get released various research centers with varying credibility. most) of us lack the expertise of picking the genuine , winning research especially in the arena of new drugs and devices. Did we follow up ?
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content